STOCKHOLM, March 23, 2021 /PRNewswire/ -- IRRAS, a
global healthcare company with a comprehensive portfolio of
innovative products for neurocritical care, today announced
that company management will present at the Swedish Investment Bank
Redeye on March 30 at 4:00 pm-5:00pm CET.
Kleanthis G. Xanthopoulos, Ph.D.,
CEO and Will Martin, President and
CCO will present the IRRAS strategy and answer follow up questions.
In total the presentation and the Q&A session is estimated to
take one hour.
A link with an invitation which will be webcast live is
presented below.
https://www.redeye.se/events/806966/strategy-update-irras
The presentation will also be made available
on www.irras.com.
About IRRAS
IRRAS is a global medical care company focused on delivering
innovative medical solutions to improve the lives of critically ill
patients. IRRAS designs, develops, and commercializes neurocritical
care products that transform patient outcomes and decrease the
overall cost of care by addressing complications associated with
current treatment methodologies. IRRAS markets and sells its
comprehensive, innovative IRRAflow and Hummingbird ICP
Monitoring product lines to hospitals worldwide through its direct
sales organization in the United
States and select European countries as well as an
international network of distribution partners.
IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in
Munich, Germany, and San Diego, California, USA. For more
information, please visit www.irras.com.
IRRAS AB (publ) is listed on Nasdaq Stockholm (ticker:
IRRAS).
For more information, please contact:
USA
Kleanthis G. Xanthopoulos,
Ph.D.
CEO
ir@irras.com
Europe
Sabina Berlin
CFO
+46 73 951 95 02
sabina.berlin@irras.com
The information was released for public disclosure, through
the agency of the contact person above, on March 23, 2021 at 08:00 (CET).
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/irras/r/irras-to-present-at-redeye,c3311974